You are here
Dr Josh Osowicki
Dr Josh Osowicki is a clinician-scientist who completed his PhD in the MCRI Tropical Diseases research group where he was supervised by Prof. Andrew Steer to establish a human challenge model of Strep A (Streptococcus pyogenes, group A Streptococcus) pharyngitis to accelerate vaccine development against this high priority pathogen. Josh worked with a multinational team of investigators to select and characterise a human challenge strain, design the study protocol, and undertake an initial dose-finding trial to establish the safety and reliability of the model. Josh works clinically as a consultant Paediatric Infectious Diseases physician at the Royal Children's Hospital Melbourne.
Josh is a Paediatric Infectious Diseases physician at the Royal Children's Hospital and completed his PhD as a student of the University of Melbourne. He is a member of the Lancefield Society (https://www.lancefieldsociety.org/). He is or has been a member of major Australasian, European, and American infectious diseases and/or microbiology organisations.
MCRI Clinician-Scientistst Fellowship 2021
NHMRC Gustav Nossal Postgraduate Scholarship 2017-2020
Josh's ongoing research spans infection, immunity, vaccine development, and human challenge research related to Strep A and other pathogens. He is carrying on work with samples from the initial CHIVAS-M75 dose-finding human challenge trial, and focussing on trials to evaluate new Strep A vaccines and advance development of long-acting penicillins using the CHIVAS challenge model. Josh is working with human challenge researchers and bioethicists to explore the participant experience in these trials and improve approaches to recruitment and informed consent. With local and national collaborators, Josh is helping to consolidate and advance human challenge research in Australia as a tool to advance solutions against local and global infectious diseases. Alongside this program, Josh enjoys the 'distraction' of smaller projects arising opportunistically from his clinical work.
Controlled Human Infection for Vaccination Against Strep A (CHIVAS) human challenge model.
Controlled Human Infection for Penicillin Against Strep A – a double blinded randomised trail (The CHIPS trial) - https://www.telethonkids.org.au/projects/the-chips-trial/
Australian Strep A Vaccine Initiative (ASAVI) - https://www.telethonkids.org.au/projects/australian-strep-a-vaccine-init...
A controlled human infection model of Streptococcus pyogenes pharyngitis (CHIVAS-M75): an observational, dose-finding study,
An emm-type specific qPCR to track bacterial load during experimental human Streptococcus pyogenes pharyngitis. Fabri LV, Azzopardi KI, Osowicki J, Frost HR, Smeesters PR, Steer AC.
BMC Infect Dis. 2021 PMID: 34020607
Refractory thoracic conidiobolomycosis treated with mepolizumab immunotherapy.
Yeoh DK, Saunders T, Butters C, Burgner D, Bryant PA, Cain TM, Ng J, Gwee A, Daley AJ, Cole T, Curtis N, Harrison J, Osowicki J. J Allergy Clin Immunol Pract. 2021 PMID: 33601049
A Systematic Review and Meta-analysis of Upper Airway Swab Collection for Detection of Viral and Bacterial Pathogens by Individuals or Caregivers Compared to Health Care Workers.
Harrison C, Lindholm DE, Steer AC, Osowicki J. J Clin Microbiol. 2021 PMID: 33468606
Payment in challenge studies: ethics, attitudes and a new payment for risk model.
Grimwade O, Savulescu J, Giubilini A, Oakley J, Osowicki J, Pollard AJ, Nussberger AM.
J Med Ethics. 2020 PMID: 32978306
Incidence of acute rheumatic fever and rheumatic heart disease in Melbourne, Australia from 1937 to 2013. Oliver J, Osowicki J, Cordell B, Hardy M, Engelman D, Steer AC. J Paediatr Child Health. 2020.
Diagnosis of rheumatic fever: the need for a better test.
Osowicki J, Steer AC. Arch Dis Child. 2020 PMID: 32601088
Third human challenge trial conference, Oxford, United Kingdom, February 6-7, 2020, a meeting report. Pollard AJ, Sauerwein R, Baay M, Neels P; HCT3 speakers and session chairs.
Biologicals. 2020 PMID: 32505512
Controlled human infection for vaccination against Streptococcus pyogenes (CHIVAS): Establishing a group A Streptococcus pharyngitis human infection study.
Osowicki J, Azzopardi KI, Baker C, Waddington CS, Pandey M, Schuster T, Grobler A, Cheng AC, Pollard AJ, McCarthy JS, Good MF, Walker MJ, Dale JB, Batzloff MR, Carapetis JR, Smeesters PR, Steer AC.
Vaccine. 2019 PMID: 31101422
Potential for Molecular Testing for Group A Streptococcus to Improve Diagnosis and Management in a High-Risk Population: A Prospective Study.
Ralph AP, Holt DC, Islam S, Osowicki J, Carroll DE, Tong SYC, Bowen AC. Open Forum Infect Dis. 2019
A Controlled Human Infection Model of Group A Streptococcus Pharyngitis: Which Strain and Why?
Osowicki J, Azzopardi KI, McIntyre L, Rivera-Hernandez T, Ong CY, Baker C, Gillen CM, Walker MJ, Smeesters PR, Davies MR, Steer AC. mSphere. 2019 PMID: 30760615
International survey of paediatric infectious diseases consultants on the management of community-acquired pneumonia complicated by pleural empyema.
Osowicki J, Steer AC. J Paediatr Child Health. 2019 PMID: 30051535
WHO/IVI global stakeholder consultation on group A Streptococcus vaccine development: Report from a meeting held on 12-13 December 2016.
Osowicki J, Vekemans J, Kaslow DC, Friede MH, Kim JH, Steer AC. Vaccine. 2018 PMID: 29496349
Rheumatic fever: The rebound phenomenon returns.
Osowicki J, Carr JP, Steer AC. J Paediatr Child Health. 2018 PMID: 29411467
The long shadow of Lemierre's syndrome.
Osowicki J, Kapur S, Phuong LK, Dobson S. J Infect. 2017 PMID: 28646962
Antibiotic duration and timing of the switch from intravenous to oral route for bacterial infections in children: systematic review and guidelines.
McMullan BJ, Andresen D, Blyth CC, Avent ML, Bowen AC, Britton PN, Clark JE, Cooper CM, Curtis N, Goeman E, Hazelton B, Haeusler GM, Khatami A, Newcombe JP, Osowicki J, Palasanthiran P, Starr M, Lai T, Nourse C, Francis JR, Isaacs D, Bryant PA; ANZPID-ASAP group. Lancet Infect Dis. 2016 PMID: 27321363
Congenital Tuberculosis Complicated by Hemophagocytic Lymphohistiocytosis.
Osowicki J, Wang S, McKenzie C, Marshall C, Gard J, Ke Juin W, Steer AC, Connell TG.
Pediatr Infect Dis J. 2016 Jan;35(1):108-10. doi: 10.1097/INF.0000000000000932.
PMID: 26398869 Review.
Australia-wide Point Prevalence Survey of Antimicrobial Prescribing in Neonatal Units: How Much and How Good?
Osowicki J, Gwee A, Noronha J, Britton PN, Isaacs D, Lai TB, Nourse C, Avent M, Moriarty P, Francis JR, Blyth CC, Cooper CM, Bryant PA; ANZPID-ASAP group (Australian and New Zealand Paediatric Infectious Diseases-Australasian Stewardship of Antimicrobials in Paediatrics).
Pediatr Infect Dis J. 2015 Aug;34(8):e185-90. doi: 10.1097/INF.0000000000000719.
Australia-wide point prevalence survey of the use and appropriateness of antimicrobial prescribing for children in hospital.
Osowicki J, Gwee A, Noronha J, Palasanthiran P, McMullan B, Britton PN, Isaacs D, Lai T, Nourse C, Avent M, Moriarty P, Clark J, Francis JR, Blyth CC, Cooper CM, Bryant PA. Med J Aust. 2014 PMID: 25495311
A pointed question: is a child at risk following a community-acquired needlestick injury?
Osowicki J, Curtis N.
Arch Dis Child. 2014 PMID: 25165072
The impact of an infectious diseases consultation on antimicrobial prescribing.
Osowicki J, Gwee A, Noronha J, Palasanthiran P, McMullan B, Britton PN, Isaacs D, Lai T, Nourse C, Avent M, Moriarty P, Clark J, Francis JR, Blyth CC, Cooper CM, Bryant PA. Pediatr Infect Dis J. 2014
Josh was supported by an NHMRC Gustav Nossal Postgraduate Scholarship and the END RHD CRE over the course of his PhD.
Funding for his ongoing work includes grants from NHMRC and the Heart Foundation.